



ASX Announcement

20 February 2020

EAGLE & ZOONO EXECUTE DISTRIBUTION AGREEMENT FOR CHINA TERRITORY

Eagle Health Holdings Limited (ASX: EHH) (“Eagle”) is pleased to announce that it has entered into a Distribution Agreement (the “**Agreement**”) with Zoono Group Limited (**ASX: ZNO**) (“**Zoono**” or “**ZNO**”) for distributing Zoono’s products in China.

In accordance with the Agreement, Eagle and Zoono have a “co-branding” arrangement whereby Eagle will arrange for the bulk import of Zoono’s formulations to its wholly owned GMP certified pharmaceutical facility in Xiamen China, where Eagle will carry out the labelling, packaging and distribution into Eagle’s extensive existing channels. Under the co-branding arrangement Zoono’s formulations will carry the renowned and trusted Eagle logo, with bilingual packaging, indicating “powered by” Zoono.

Eagle will have exclusive distribution rights to the Eagle ‘co-branded’ products, as well as holding preferred partner status for Zoono branded products for offline retail sales.

Eagle has more than 300 Zhang Lao San exclusive product stores and franchised stores throughout China, with a further 271 distribution partners placing Eagle’s branded products into circa 30,000 outlets across the country.

In part due to the Coronavirus (type ‘Covid-19’) epidemic, there is now unprecedented interest in Zoono Technology and its proven activity against ‘corona type’ viruses and bacteria as well as its ability to prevent cross contamination with its 24 hour to 30 day extended efficacy (by application)¹.

Eagle is receiving accelerated co-operation from Xiamen’s local government agencies to expand its GMP pharmaceutical facilities and registrations to facilitate the packaging and distribution of Zoono products. Eagle’s brand new and purposefully ordered high-speed automated machinery has now been delivered to its Xiamen facility and is currently being commissioned.

Chinese authorities are placing top priority on assisting companies with products and services associated with combating and controlling the spread of the Coronavirus. On this basis and from the most recent dialogue with the local authorities, Eagle expects the appropriate licenses to be granted to the Xiamen facility upon completion of inspection in the coming days.

The first shipment from Zoono (approximately 4 tonne of product) is being prepared for immediate air-freight and transport to Eagle’s Xiamen facility.

¹ – refer Zoono Group Limited’s (ASX: ZNO) ASX announcement dated 30 January 2020 titled “Coronavirus Update” and www.zoono.com

Key terms of the Agreement:

1. An initial 3-year term with 5-year rights of renewal;
2. Minimum purchase volumes of:
 - NZD\$1,500,000 in the first 12 months;
 - NZD\$2,300,000 in year two; and
 - NZD\$3,100,000 in year three;and thereafter increasing by 10% per annum.
3. Initial Order of Zoono products is NZD\$400,000;
4. Eagle granted exclusivity for co-branded products; and
5. Zoono (sole label) may be sold by Eagle as a preferred partner with good faith negotiations after 12 months for securing exclusivity for further channels.

The Zoono Agreement is the first of a number of ongoing initiatives generated by the newly established Australian based Eagle team. Eagle looks forward to further updating its shareholders on further developments.

Approved for release by the full Board of Directors.

-ENDS-

Contact:

Henko Vos, Company Secretary

Email: henko.vos@nexasperth.com.au

About Eagle Health Holdings Limited

Eagle is an ASX listed vertically integrated health and nutritional products business which develops, manufactures and distributes products into 26 provinces in China. Eagle has collectively more than 300 Zhang Lao San exclusive product stores and franchised stores throughout China, with a further 271 distribution partners placing Eagle's branded products into more than 30,000 outlets across the country. Eagle produces a range of traditional Chinese Medicine and Western nutritional products including amino acids, protein supplements, lozenges and dendrobium oil. Eagle has a GMP certified manufacturing facility and a Head Office in Xiamen, China, acting as a central hub for distribution into Chinese pharmacies, health food stores, trading companies and supermarkets. Eagle has a corporate and sales office in Melbourne, Australia. Eagle has a stated strategy of acquiring or partnering with quality Australian products for distribution into China.

For more information visit: www.auehh.com.au or www.eaglehealthltd.com/EN/index.aspx

About Zoono Group Limited

Zoono Group Limited is a New Zealand based corporation listed on the ASX. ZNO is currently experiencing unprecedented demand for its products. ZNO is a global biotech company that develops, manufactures and distributes a suite of scientifically-validated, long-lasting and environmentally-friendly antimicrobial solutions based on 'zoono molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould. To learn more, please visit: www.zoono.com